Stockscreener 앱 받기
116.36
0.84%
1.62
전일 마감가:
$114.74
열려 있는:
$114
하루 거래량:
95,785
Relative Volume:
0.04
시가총액:
$15.09B
수익:
$692.26M
순이익/손실:
$-512.41M
주가수익비율:
-27.44
EPS:
-4.24
순현금흐름:
$-274.36M
1주 성능:
+0.72%
1개월 성능:
+12.35%
6개월 성능:
+160.47%
1년 성능:
+146.28%
1일 변동 폭
$113.53
$116.70
1주일 범위
$110.31
$120.74
52주 변동 폭
$34.88
$120.74
가든트헬스 Stock (GH) Company Profile
명칭
Guardant Health Inc
전화
855-698-8887
주소
3100 HANOVER STREET, PALO ALTO
GH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
116.18 | 14.90B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
628.62 | 235.43B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
236.81 | 167.20B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
699.91 | 55.72B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
240.96 | 40.77B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
136.45 | 38.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
가든트헬스 Stock (GH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-12-02 | 재개 | Morgan Stanley | Overweight |
| 2025-09-25 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | 재개 | Wells Fargo | Overweight |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-06-28 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-24 | 재개 | Craig Hallum | Buy |
| 2023-12-14 | 개시 | Guggenheim | Neutral |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-09-27 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-05 | 개시 | UBS | Buy |
| 2023-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-11-01 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | 개시 | Craig Hallum | Buy |
| 2022-10-06 | 개시 | Stephens | Overweight |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-06-03 | 개시 | Piper Sandler | Overweight |
| 2022-04-28 | 재개 | BTIG Research | Buy |
| 2022-02-24 | 재확인 | Canaccord Genuity | Buy |
| 2022-02-24 | 재확인 | Citigroup | Buy |
| 2022-02-24 | 재확인 | Cowen | Outperform |
| 2022-02-24 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-24 | 재확인 | SVB Leerink | Outperform |
| 2022-02-24 | 재확인 | Stifel | Buy |
| 2022-02-24 | 재확인 | Wells Fargo | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-05-25 | 개시 | Wells Fargo | Overweight |
| 2021-01-11 | 개시 | Stifel | Buy |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-06-12 | 개시 | BTIG Research | Buy |
| 2020-02-21 | 개시 | Guggenheim | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-08-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-04-16 | 개시 | Canaccord Genuity | Buy |
| 2019-04-10 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | 재확인 | BofA/Merrill | Neutral |
| 2018-10-29 | 개시 | BofA/Merrill | Neutral |
| 2018-10-29 | 개시 | JP Morgan | Overweight |
| 2018-10-29 | 개시 | William Blair | Outperform |
모두보기
가든트헬스 주식(GH)의 최신 뉴스
Guggenheim Raises Price Target on Guardant Health (GH) to $135 | GH Stock News - GuruFocus
Guardant Health: Look For Explosive Revenue Growth Ahead (NASDAQ:GH) - Seeking Alpha
Y Intercept Hong Kong Ltd Has $4.77 Million Holdings in Guardant Health, Inc. $GH - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Acquires 106,263 Shares of Guardant Health, Inc. $GH - MarketBeat
Baillie Gifford & Co. Increases Position in Guardant Health, Inc. $GH - MarketBeat
Guardant Health (GH): Court Decision Offers Incremental Positive in Litigation - GuruFocus
Leerink Partners Maintains Guardant Health(GH.US) With Buy Rating - 富途资讯
Guardant Can Try Again To Nix Patent Tied To $83M Verdict - Law360
Wall Street Has a Positive Opinion on Guardant Health (GH) - Finviz
Guardant Health, Inc. $GH is Emerald Mutual Fund Advisers Trust's 8th Largest Position - MarketBeat
Insider Sell: Terilyn Monroe Sells 8,571 Shares of Guardant Heal - GuruFocus
Guardant Health CPO Monroe sells $977k in stock By Investing.com - Investing.com UK
Guardant Health (NASDAQ:GH) Insider Sells $977,865.39 in Stock - MarketBeat
Guardant Health CPO Monroe sells $977k in stock - Investing.com
Avoiding Lag: Real-Time Signals in (GH) Movement - Stock Traders Daily
AI Diagnostics Co.'s Patent Claims Don't Pass Alice Test - Law360
FDA Approves Guardant Health's Blood Test To Guide Treatment For Advanced Colorectal Cancer - Benzinga
Analysts turn more bullish on Guardant Health, Inc. (GH) as 2026 growth catalysts build - MSN
Guardant Health, Inc. Receives FDA Approval for Guardant360®? CDx as Companion Diagnostic for BRAFTOVI®? (Encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer - marketscreener.com
FDA Approves Guardant Health's (GH) Diagnostic for Colorectal Ca - GuruFocus
FDA Approval Boosts Guardant Health (GH) with New Diagnostic Use - GuruFocus
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer - Yahoo Finance
Guardant Health, Inc. $GH Shares Bought by Emerald Advisers LLC - MarketBeat
Guardant Health (NASDAQ:GH) Hits New 12-Month HighHere's Why - MarketBeat
Is Merck’s Guardant Liquid Biopsy Alliance Reshaping the Investment Case for MRK? - Yahoo Finance
Strong Results and Improved Guidance Lifted Guardant Health (GH) in Q4 - Insider Monkey
Inspire Advisors LLC Makes New Investment in Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. (NASDAQ:GH) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Analysts Turn More Bullish on Guardant Health, Inc. (GH) as 2026 Growth Catalysts Build - Insider Monkey
Guardant Health’s Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families in North Carolina - New Bern Live
Guardant Health (GH) Joins Forces with Merck for Oncology Advancements - GuruFocus
Guardant Health announces multi-year strategic collaboration agreement with Merck for companion diagnostics - BioSpectrum Asia
Guardant Health Announces Multi-Year Strategic Collaboration Agreement With Merck - TradingView — Track All Markets
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform - Chartmill
Campbell & CO Investment Adviser LLC Makes New $1.19 Million Investment in Guardant Health, Inc. $GH - MarketBeat
Guardant Health: Shield Colorectal Cancer Screening To Sustain Growth - Seeking Alpha
Guardant Health stock hits 52-week high at 113.98 USD By Investing.com - Investing.com Nigeria
IPO Launch: How does Guardant Health Inc compare to its peersJuly 2025 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn
Guardant Health stock hits 52-week high at 113.98 USD - Investing.com India
Sumitomo Mitsui Trust Group Inc. Has $47.12 Million Position in Guardant Health, Inc. $GH - MarketBeat
Global Pan-Genomic and Multi-Gene Panel Testing Market Forecast to Hit US$ 25.91 Billion by 2032 at 12.04% CAGR, Driven by Growing Demand for Comprehensive Multi-Gene Diagnostics: AnalystView Market Insights - GlobeNewswire Inc.
BLOODPAC Publishes New Standards for Liquid Biopsy Tests That Monitor for Cancer Recurrence - PA Media
Guardant Health (NASDAQ:GH): Strongest Q3 Results from the Testing & Diagnostics Services Group - Yahoo Finance
Guardant Health Announces Strong 2025 Preliminary Revenue Growth - The Globe and Mail
Guardant Health guides Q4 and FY25 revenue above consensus - MSN
Guardant Health (NASDAQ:GH) Reaches New 12-Month HighStill a Buy? - MarketBeat
Guardant Health shares up 2.4% after preliminary Q4 revenue beats estimates - marketscreener.com
Guardant Health, Inc. (GH) Stock Analysis: Strong Buy Potential with 38.5% Revenue Growth and Robust Analyst Support - DirectorsTalk Interviews
Guardant Health rises after Q4 revenue surpasses estimate - TradingView — Track All Markets
Guardant Health, Inc. $GH Shares Sold by D.A. Davidson & CO. - MarketBeat
Guardant Health Sees 39% Rise in Q4 Preliminary Revenue - marketscreener.com
가든트헬스 (GH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.49%
0.89%
자본화:
|
볼륨(24시간):